This single-center, 400-patient, randomized controlled trial assesses the impact of a patient- and provider-facing EPIC Best Practice Advisory (BPA; alert-based computerized decision support tool) to increase guideline-directed utilization of statin and statin-alternative oral LDL-C lowering therapies in patients with PAD who are not being prescribed LDL-C-lowering therapy.
All patients ≥ 18 years old
Seen in Cardiovascular Medicine Clinic, Primary Care, Podiatry, Vascular Surgery, and Diabetology
Medical history entry, visit diagnosis, or problem list entry of PAD
Not prescribed LDL-C-lowering therapy
Patients taking a statin, ezetimibe, bempedoic acid, a PCSK9 inhibitor, inclisiran or a combination will be excluded
Brigham and Women's Hospital
Lead sponsor
Esperion Therapeutics, Inc.
Collaborator